Oryzon Genomics S.A.
Oryzon Genomics S.A. (ORYZF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Oryzon Genomics S.A. (ORYZF), covering cash flow, earnings, and balance sheets.
Oryzon Genomics S.A. (ORYZF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Oryzon Genomics S.A. ORYZF financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $7.36M | $0.00 | $4.11M |
| Cost of Revenue | $0.00 | $302189.00 | $0.00 | $170475.00 |
| Gross Profit | $0.00 | $7.06M | $0.00 | $3.94M |
| Gross Profit Ratio | $0.00 | $0.96 | $0.00 | $0.96 |
| R&D Expenses | $2.39M | $6.83M | $1.92M | $647984.00 |
| SG&A Expenses | $1.08M | $500125.00 | $879000.00 | $980716.00 |
| Operating Expenses | $3.47M | $1.70M | $2.79M | $3.10M |
| Total Costs & Expenses | $3.47M | $2.00M | $2.79M | $3.25M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $31399.00 | $36937.00 | $32589.00 | $14722.00 |
| EBITDA | -$3.44M | $5.24M | -$2.79M | $850470.00 |
| EBITDA Ratio | $0.00 | $0.71 | $0.00 | $0.21 |
| Operating Income | -$3.47M | $5.36M | -$2.79M | $835748.00 |
| Operating Income Ratio | $0.00 | $0.73 | $0.00 | $0.20 |
| Other Income/Expenses (Net) | $1.77M | -$8.47M | $1.42M | -$2.74M |
| Income Before Tax | -$1.70M | -$3.12M | -$1.38M | -$1.90M |
| Income Before Tax Ratio | $0.00 | -$0.42 | $0.00 | -$0.46 |
| Income Tax Expense | $0.00 | $1.91M | $0.00 | -$2.008M |
| Net Income | -$1.70M | -$1.21M | -$1.38M | $107172.00 |
| Net Income Ratio | $0.00 | -$0.16 | $0.00 | $0.03 |
| EPS | -$0.03 | -$0.02 | -$0.02 | $0.002 |
| Diluted EPS | -$0.03 | -$0.02 | -$0.02 | $0.002 |
| Weighted Avg Shares Outstanding | $64.75M | $64.37M | $63.38M | $61.22M |
| Weighted Avg Shares Outstanding (Diluted) | $64.75M | $64.37M | $63.38M | $61.22M |
Over the past four quarters, Oryzon Genomics S.A. demonstrated steady revenue growth, increasing from $4.11M in Q2 2024 to $0.00 in Q1 2025. Operating income reached -$3.47M in Q1 2025, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$3.44M, reflecting operational efficiency. Net income dropped to -$1.70M, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan